Last edition
News about "accelerating innovative therapies"
Healx Doses First Patient in Phase 1/2 Trial of AI-Discovered Therapy for Relapsed Osteosarcoma
Healx has dosed the first patient in its Phase 1/2 trial of AI-developed investigational therapy HLX-4310, marking a milestone in the development of novel treatments aimed at preventing metastatic recurrence in osteosarcoma and other rare cancers.
Accelerating Innovative Therapies | 24/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members